4D Molecular Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	48.56	149.34	249.11	52.35	153	276.73
Short-Term Investments	256.51	275.54	39.12	161.2	94.78	-
Cash & Short-Term Investments	305.06	424.88	288.23	213.55	247.78	276.73
Cash Growth	-39.22%	47.41%	34.97%	-13.81%	-10.46%	457.33%
Accounts Receivable	-	-	-	-	0.05	1.49
Other Receivables	-	-	-	-	0.7	-
Receivables	-	-	-	-	0.75	1.49
Prepaid Expenses	7.31	10.06	8.36	6.96	7.76	4.44
Total Current Assets	312.38	434.93	296.59	220.51	256.28	282.66
Property, Plant & Equipment	35.06	40.61	31.67	35.35	28.95	5.07
Long-Term Investments	67.17	80.58	10.95	4.91	67.65	-
Other Long-Term Assets	9.38	4.26	0.68	1.08	0.6	0.6
Total Assets	423.98	560.38	339.89	261.85	353.49	288.33
Accounts Payable	6.86	4.39	3.52	3.32	4.76	1.79
Accrued Expenses	24.19	18.87	12.01	8.87	7.74	8.37
Current Portion of Leases	5.7	5.64	3.15	2.66	1.23	-
Current Unearned Revenue	0.36	0.26	0.27	0.88	2.6	6.59
Total Current Liabilities	37.11	29.15	18.95	15.73	16.34	16.74
Long-Term Leases	16.57	18.97	11.52	13.47	15.22	-
Long-Term Unearned Revenue	0.84	1.06	0.97	1.08	2.49	13.23
Other Long-Term Liabilities	0.49	0.6	0.62	0.23	0.33	1.97
Total Liabilities	55	49.78	32.06	30.51	34.38	31.94
Common Stock	0.01	0.01	0	0	0	0
Additional Paid-In Capital	1,104	1,087	723.14	547.02	526.52	392.06
Retained Earnings	-735.7	-576.2	-415.33	-314.49	-207	-135.68
Comprehensive Income & Other	0.67	0.23	0.02	-1.2	-0.42	-
Total Common Equity	368.98	510.61	307.83	231.34	319.11	256.39
Shareholders' Equity	368.98	510.61	307.83	231.34	319.11	256.39
Total Liabilities & Equity	423.98	560.38	339.89	261.85	353.49	288.33
Total Debt	22.26	24.61	14.67	16.12	16.45	-
Net Cash (Debt)	349.97	480.85	284.52	202.34	298.98	276.73
Net Cash Growth	-33.45%	69.01%	40.61%	-32.32%	8.04%	457.33%
Net Cash Per Share	6.26	8.91	7.27	6.25	10.78	43.03
Filing Date Shares Outstanding	57.14	46.3	49.78	33.23	32.24	26.69
Total Common Shares Outstanding	46.77	45.79	43.08	32.63	32.22	26.68
Working Capital	275.27	405.78	277.64	204.78	239.94	265.91
Book Value Per Share	7.89	11.15	7.15	7.09	9.90	9.61
Tangible Book Value	368.98	510.61	307.83	231.34	319.11	256.39
Tangible Book Value Per Share	7.89	11.15	7.15	7.09	9.90	9.61
Machinery	17.7	17.17	14.61	12.61	7.12	5.85
Construction In Progress	0.05	1.18	0.55	0.48	10.07	0.54
Leasehold Improvements	18.47	17.76	16.9	16.9	2.53	2.53

Updated Nov 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q